<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="helma.xsl"?>
<xmlroot xmlns:hop="http://www.helma.org/docs/guide/features/database">
  <hopobject id="2432" name="Page" prototype="Page" created="1363280116832" lastModified="1543370270745">
  <hop:parent idref="0" prototyperef="Root"/>
    <http_browser>Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1)</http_browser>
    <lang>en-us</lang>
    <uri>bone-update</uri>
    <http_host>127.0.0.1:8080</http_host>
    <time type="date">28.11.2018 01:57:50 UTC</time>
    <pseudoparent idref="0" prototyperef="Root"/>
    <http_remotehost>127.0.0.1</http_remotehost>
    <hopsession>127.0.0.mj5tu6ftnzvm</hopsession>
    <user>default</user>
    <pvcount type="float">85.0</pvcount>
    <body>Gloomy tales &lt;a href=&quot;http://starbizzcon.com/stmap_45db0.html?sinequan.megalis.confido.levitra&quot;&gt;pro grade k20 by jay lab project&lt;/a&gt;  A combination treatment from the drugmaker for melanoma, thedeadliest form of skin cancer, has won priority review from U.S.regulators. The move means the Food and Drug Administration willnow decide whether to approve the dual use of Tafinlar, alsoknown as dabrafenib, and Mekinist, or trametinib, by earlyJanuary.
 </body>
    <http_language>en-US,en;q=0.8</http_language>
    <is_xhtml type="boolean">true</is_xhtml>
    <http_referer>http://beagleboard.org/bone-update/edit</http_referer>
  </hopobject>
</xmlroot>
